Ameritas Investment Partners Inc. Has $1.38 Million Stock Holdings in Haemonetics Co. (NYSE:HAE)

Ameritas Investment Partners Inc. trimmed its stake in Haemonetics Co. (NYSE:HAE) by 1.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,207 shares of the medical instruments supplier’s stock after selling 190 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Haemonetics were worth $1,383,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Covestor Ltd lifted its stake in shares of Haemonetics by 184.8% in the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock valued at $58,000 after buying an additional 438 shares in the last quarter. Edgestream Partners L.P. purchased a new position in shares of Haemonetics in the first quarter worth about $1,723,000. State Board of Administration of Florida Retirement System increased its stake in shares of Haemonetics by 15.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 16,475 shares of the medical instruments supplier’s stock worth $1,363,000 after purchasing an additional 2,160 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Haemonetics by 4.7% in the first quarter. ProShare Advisors LLC now owns 11,490 shares of the medical instruments supplier’s stock worth $981,000 after purchasing an additional 516 shares in the last quarter. Finally, Isthmus Partners LLC increased its stake in shares of Haemonetics by 168.5% in the first quarter. Isthmus Partners LLC now owns 48,038 shares of the medical instruments supplier’s stock worth $4,100,000 after purchasing an additional 30,150 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Trading Up 0.8 %

Shares of HAE traded up $0.73 during mid-day trading on Wednesday, reaching $92.31. The company’s stock had a trading volume of 178,657 shares, compared to its average volume of 513,247. The stock has a market cap of $4.70 billion, a PE ratio of 39.99, a P/E/G ratio of 1.65 and a beta of 0.29. The company has a current ratio of 2.56, a quick ratio of 1.50 and a debt-to-equity ratio of 0.83. Haemonetics Co. has a 52 week low of $70.74 and a 52 week high of $97.97. The company’s fifty day moving average price is $87.35 and its two-hundred day moving average price is $83.80.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.02. The firm had revenue of $343.00 million during the quarter, compared to analyst estimates of $329.53 million. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The business’s quarterly revenue was up 12.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.77 EPS. On average, analysts predict that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on HAE. Needham & Company LLC raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a research note on Wednesday, June 12th. Barrington Research boosted their price objective on shares of Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. Finally, JMP Securities boosted their price objective on shares of Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research note on Friday, May 10th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $109.50.

Insider Activity at Haemonetics

In related news, insider Stewart W. Strong sold 733 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total transaction of $70,397.32. Following the completion of the sale, the insider now directly owns 15,608 shares in the company, valued at approximately $1,498,992.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Haemonetics news, insider Stewart W. Strong sold 686 shares of the business’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $95.11, for a total transaction of $65,245.46. Following the transaction, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,730,621.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Stewart W. Strong sold 733 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total transaction of $70,397.32. Following the transaction, the insider now directly owns 15,608 shares in the company, valued at $1,498,992.32. The disclosure for this sale can be found here. Insiders sold 29,516 shares of company stock worth $2,638,056 in the last three months. 1.80% of the stock is owned by insiders.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.